In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 187973-60-0, name is 6-Iodopyridazin-3-amine, introducing its new discovery. Product Details of 187973-60-0
FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 187973-60-0, and how the biochemistry of the body works.Product Details of 187973-60-0
Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2937 – PubChem